Exicure, Inc. (XCUR)
NASDAQ: XCUR · IEX Real-Time Price · USD
0.535
+0.231 (76.02%)
At close: Jul 19, 2024, 4:00 PM
0.390
-0.145 (-27.12%)
Pre-market: Jul 22, 2024, 7:24 AM EDT
Company Description
Exicure, Inc. does not have significant operations.
previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets.
Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Exicure, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Paul Kang |
Contact Details
Address: 2430 N. Halsted St. Chicago, Illinois 60614 United States | |
| Phone | 847-673-1700 |
| Website | exicuretx.com |
Stock Details
| Ticker Symbol | XCUR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001698530 |
| CUSIP Number | 30205M101 |
| ISIN Number | US30205M2008 |
| Employer ID | 81-5333008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Paul Kang | Chief Executive Officer and Director |
| Jiyoung Hwang | Chief Financial Officer and Director |
| Joshua Miller | Chief Accounting Officer |
| Bart Anderson | Senior Director of Research & Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 19, 2024 | PRE 14A | Other preliminary proxy statements |
| Jul 2, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jul 1, 2024 | 8-K | Current Report |
| Jun 25, 2024 | 8-K | Current Report |
| Jun 17, 2024 | 10-Q | Quarterly Report |
| Jun 17, 2024 | 8-K | Current Report |
| Jun 11, 2024 | ARS | Filing |
| Jun 11, 2024 | DEF 14A | Other definitive proxy statements |
| Jun 6, 2024 | 10-K | Annual Report |
| Jun 6, 2024 | 8-K | Current Report |